GlassScriptPhysician profile
Emily Foreit
NPI 1477175651
$7,928.27
in general payments reported to CMS, 2019-2025
27 companies · $1,657 in 2025
The $1,657 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $211 · 2022: $1,481 · 2023: $1,831 · 2024: $2,748 · 2025: $1,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,944 · Education: $292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,944.10 |
| Education | $292.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,371.57 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $958.25 | 2022-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $947.71 | 2022-2025 | Dupixent |
| Genzyme Corporation | $681.53 | 2022-2025 | |
| Janssen Biotech, INC. | $505.73 | 2023-2025 | Tremfya |
| Dermavant Sciences, INC. | $456.20 | 2022-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $418.45 | 2021-2025 | Absorica Ld, Winlevi |
| Ucb, INC. | $326.37 | 2024-2025 | Bimzelx |
| Pfizer INC. | $324.58 | 2022-2025 | |
| Lilly USA, LLC | $253.88 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Scientific Affairs, LLC | $246.60 | 2022 | |
| Leo Pharma INC. | $240.18 | 2021-2025 | Adbry, Anzupgo |
| Incyte Corporation | $238.21 | 2021-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $223.06 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $206.95 | 2021-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $117.51 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $105.54 | 2024-2025 | Nemluvio |
| Amgen INC. | $105.08 | 2024-2025 | Otezla, Otezla |
| Almirall LLC | $40.83 | 2022 | |
| Arcutis Biotherapeutics, INC. | $33.86 | 2023-2024 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.96 | 2025 | Jublia, Cabtreo |
| Verrica Pharmaceuticals INC. | $22.82 | 2024 | Ycanth |
| Allergan, INC. | $19.44 | 2021 | |
| Botanix Sb INC | $16.74 | 2025 | Sofdra |
| Journey Medical Corporation | $15.85 | 2022 | |
| Vyne Pharmaceuticals INC. | $15.31 | 2021 | |
| Stemline Therapeutics INC. | $12.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Foreit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.